Nuvo Pharmaceuticals Inc MRVFF

Pennsaid not recommended because of cost!

[711666]

https://formulary.drugplan.health.gov.sk.ca/FormularyBulletins/Bulletin103Jul2005.pdf Diclofenac sodium, topical solution, 1.5% (Pennsaid-SLV). The clinical benefit does not justify the incremental cost. ++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++ https://www.health.gov.nl.ca/health/nlpdp/newspdfiles/NLPDPSpring2006.pdf The Atlantic Common Drug Review (ACDR) is a regional review process that provides evidence-based recommendations for coverage of new indications and line extensions for existing medications. Drug evaluation summaries are prepared by independent reviewers based on the manufacturer’s drug submission and a systematic literature search. The drug evaluation summary is presented to the Atlantic Expert Advisory Committee who recommends the place in therapy. It is then up to each individual province to make a decision as to the coverage status. The reviews for the following products were completed by the ACDR and coverage was not recommended. As such, these products will not be considered for coverage under the NLPDP. Paxil CR Zaditor Ophthalmic Drops Diamicron MR Nexium Avandamet Pennsaid Amaryl ++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++ https://www.gov.mb.ca/health/mdbif/bulletin44.pdf Drugs reviewed but not recommended for Pharmacare reimbursement at this time: Pennsaid My understanding is PENNSAID treatment is cost effective if 1 knee is the only problem! COST: 1X dollars PENNSAID treatment 2 KNEES COST: 2X dollars Most other drugs treat the whole body! COST: 1X dollars